Annual EBITDA:
$233.18M+$113.22M(+94.39%)Summary
- As of today, CPRX annual EBITDA is $233.18 million, with the most recent change of +$113.22 million (+94.39%) on December 31, 2024.
- During the last 3 years, CPRX annual EBITDA has risen by +$180.31 million (+341.04%).
- CPRX annual EBITDA is now at all-time high.
Performance
CPRX EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Quarterly EBITDA:
$75.68M-$75.00K(-0.10%)Summary
- As of today, CPRX quarterly EBITDA is $75.68 million, with the most recent change of -$75.00 thousand (-0.10%) on September 30, 2025.
- Over the past year, CPRX quarterly EBITDA has increased by +$15.25 million (+25.24%).
- CPRX quarterly EBITDA is now -0.10% below its all-time high of $75.76 million, reached on June 30, 2025.
Performance
CPRX Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM EBITDA:
$296.64M+$15.25M(+5.42%)Summary
- As of today, CPRX TTM EBITDA is $296.64 million, with the most recent change of +$15.25 million (+5.42%) on September 30, 2025.
- Over the past year, CPRX TTM EBITDA has increased by +$85.00 million (+40.16%).
- CPRX TTM EBITDA is now at all-time high.
Performance
CPRX TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
CPRX EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1Y1 Year | +94.4% | +25.2% | +40.2% |
| 3Y3 Years | +341.0% | +194.3% | +250.2% |
| 5Y5 Years | +625.9% | +541.8% | +612.5% |
CPRX EBITDA Highs & Lows
| PeriodPeriod | Annual vs HighAnnual vs High | Annual vs LowAnnual vs Low | Quarter. vs HighQuarter. vs High | Quarter. vs LowQuarter. vs Low | TTM vs HighTTM vs High | TTM vs LowTTM vs Low | |
|---|---|---|---|---|---|---|---|
| 3Y | 3-Year | at high | +341.0% | -0.1% | +365.1% | at high | +250.2% |
| 5Y | 5-Year | at high | +625.9% | -0.1% | +365.1% | at high | +618.1% |
| All-Time | All-Time | at high | +761.4% | -0.1% | +365.1% | at high | +941.4% |
CPRX EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2025 | - | $75.68M(-0.1%) | $296.64M(+5.4%) |
| Jun 2025 | - | $75.76M(+4.0%) | $281.39M(+4.5%) |
| Mar 2025 | - | $72.83M(+0.6%) | $269.38M(+15.5%) |
| Dec 2024 | $233.18M(+94.4%) | $72.37M(+19.8%) | $233.18M(+10.2%) |
| Sep 2024 | - | $60.43M(-5.2%) | $211.64M(+72.5%) |
| Jun 2024 | - | $63.75M(+74.1%) | $122.66M(+7.4%) |
| Mar 2024 | - | $36.62M(-28.0%) | $114.24M(-4.7%) |
| Dec 2023 | $119.95M(+16.1%) | $50.84M(+278.0%) | $119.89M(+19.3%) |
| Sep 2023 | - | -$28.55M(-151.6%) | $100.53M(-35.1%) |
| Jun 2023 | - | $55.33M(+30.9%) | $154.80M(+20.8%) |
| Mar 2023 | - | $42.27M(+34.3%) | $128.14M(+24.0%) |
| Dec 2022 | $103.32M(+95.4%) | $31.48M(+22.4%) | $103.32M(+22.0%) |
| Sep 2022 | - | $25.72M(-10.3%) | $84.70M(+15.8%) |
| Jun 2022 | - | $28.67M(+64.2%) | $73.12M(+21.0%) |
| Mar 2022 | - | $17.46M(+35.9%) | $60.43M(+14.3%) |
| Dec 2021 | $52.87M(+25.3%) | $12.85M(-9.1%) | $52.87M(+8.6%) |
| Sep 2021 | - | $14.14M(-11.5%) | $48.67M(+5.1%) |
| Jun 2021 | - | $15.98M(+61.4%) | $46.32M(+12.1%) |
| Mar 2021 | - | $9.90M(+14.4%) | $41.31M(-2.1%) |
| Dec 2020 | $42.19M(+31.3%) | $8.65M(-26.7%) | $42.19M(+1.3%) |
| Sep 2020 | - | $11.79M(+7.5%) | $41.64M(-4.7%) |
| Jun 2020 | - | $10.97M(+1.8%) | $43.69M(+0.0%) |
| Mar 2020 | - | $10.78M(+33.1%) | $43.69M(+36.8%) |
| Dec 2019 | $32.12M(+191.1%) | $8.10M(-41.5%) | $31.94M(+254.4%) |
| Sep 2019 | - | $13.85M(+26.3%) | $9.01M(+169.3%) |
| Jun 2019 | - | $10.97M(+1225.8%) | -$13.01M(+57.1%) |
| Mar 2019 | - | -$974.00K(+93.4%) | -$30.31M(+14.0%) |
| Dec 2018 | -$35.26M(-89.2%) | -$14.83M(-81.5%) | -$35.26M(-36.0%) |
| Sep 2018 | - | -$8.17M(-29.2%) | -$25.93M(-17.6%) |
| Jun 2018 | - | -$6.33M(-6.8%) | -$22.05M(-10.9%) |
| Mar 2018 | - | -$5.93M(-7.6%) | -$19.89M(-6.8%) |
| Dec 2017 | -$18.63M(+0.0%) | -$5.50M(-28.2%) | -$18.63M(-6.9%) |
| Sep 2017 | - | -$4.29M(-3.0%) | -$17.43M(-2.3%) |
| Jun 2017 | - | -$4.17M(+10.7%) | -$17.04M(+3.6%) |
| Mar 2017 | - | -$4.67M(-8.5%) | -$17.68M(+8.1%) |
| Dec 2016 | -$18.64M(+8.5%) | -$4.30M(-10.2%) | -$19.24M(+8.9%) |
| Sep 2016 | - | -$3.90M(+18.8%) | -$21.12M(+5.0%) |
| Jun 2016 | - | -$4.81M(+22.8%) | -$22.22M(+0.4%) |
| Mar 2016 | - | -$6.22M(-0.6%) | -$22.30M(-9.5%) |
| Dec 2015 | -$20.36M | -$6.19M(-23.6%) | -$20.36M(-12.2%) |
| Sep 2015 | - | -$5.01M(-2.4%) | -$18.15M(-5.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2015 | - | -$4.89M(-14.1%) | -$17.25M(-12.4%) |
| Mar 2015 | - | -$4.28M(-7.7%) | -$15.35M(-5.4%) |
| Dec 2014 | -$14.56M(-41.6%) | -$3.98M(+3.1%) | -$14.56M(-9.6%) |
| Sep 2014 | - | -$4.10M(-37.5%) | -$13.29M(-6.9%) |
| Jun 2014 | - | -$2.98M(+14.8%) | -$12.43M(-2.8%) |
| Mar 2014 | - | -$3.50M(-29.7%) | -$12.09M(-17.5%) |
| Dec 2013 | -$10.29M(-97.5%) | -$2.70M(+16.6%) | -$10.29M(-13.2%) |
| Sep 2013 | - | -$3.24M(-22.4%) | -$9.09M(-27.5%) |
| Jun 2013 | - | -$2.65M(-55.7%) | -$7.13M(-28.5%) |
| Mar 2013 | - | -$1.70M(-13.1%) | -$5.55M(-6.5%) |
| Dec 2012 | -$5.21M(+13.7%) | -$1.50M(-17.3%) | -$5.21M(+9.1%) |
| Sep 2012 | - | -$1.28M(-20.3%) | -$5.73M(-2.8%) |
| Jun 2012 | - | -$1.06M(+21.8%) | -$5.58M(+5.3%) |
| Mar 2012 | - | -$1.36M(+32.8%) | -$5.89M(+2.5%) |
| Dec 2011 | -$6.04M(-34.6%) | -$2.03M(-80.4%) | -$6.04M(-15.5%) |
| Sep 2011 | - | -$1.12M(+18.4%) | -$5.23M(-4.4%) |
| Jun 2011 | - | -$1.38M(+9.0%) | -$5.01M(-1.0%) |
| Mar 2011 | - | -$1.51M(-24.5%) | -$4.96M(-10.5%) |
| Dec 2010 | -$4.49M(+38.1%) | -$1.21M(-34.6%) | -$4.49M(-1.2%) |
| Sep 2010 | - | -$902.20K(+32.0%) | -$4.44M(+7.9%) |
| Jun 2010 | - | -$1.33M(-27.1%) | -$4.82M(+8.3%) |
| Mar 2010 | - | -$1.04M(+10.2%) | -$5.25M(+27.5%) |
| Dec 2009 | -$7.25M(+33.3%) | -$1.16M(+9.5%) | -$7.25M(+26.6%) |
| Sep 2009 | - | -$1.28M(+27.0%) | -$9.87M(+14.1%) |
| Jun 2009 | - | -$1.76M(+42.0%) | -$11.49M(+5.7%) |
| Mar 2009 | - | -$3.04M(+19.7%) | -$12.18M(-12.2%) |
| Dec 2008 | -$10.86M(-116.7%) | -$3.78M(-30.2%) | -$10.86M(-32.2%) |
| Sep 2008 | - | -$2.91M(-18.4%) | -$8.21M(-31.3%) |
| Jun 2008 | - | -$2.46M(-43.1%) | -$6.25M(-19.5%) |
| Mar 2008 | - | -$1.72M(-51.2%) | -$5.23M(-4.4%) |
| Dec 2007 | -$5.01M(-73.0%) | -$1.13M(-19.8%) | -$5.01M(-5.3%) |
| Sep 2007 | - | -$947.00K(+34.0%) | -$4.76M(+7.6%) |
| Jun 2007 | - | -$1.43M(+4.1%) | -$5.15M(-26.4%) |
| Mar 2007 | - | -$1.50M(-69.1%) | -$4.08M(-57.9%) |
| Dec 2006 | -$2.90M(-59.1%) | -$884.40K(+34.0%) | -$2.58M(-52.1%) |
| Sep 2006 | - | -$1.34M(-275.4%) | -$1.70M(-375.4%) |
| Jun 2006 | - | -$357.00K | -$357.00K |
| Dec 2005 | -$1.82M(-235.6%) | - | - |
| Dec 2004 | -$542.60K(-24.9%) | - | - |
| Dec 2003 | -$434.30K(-69.7%) | - | - |
| Dec 2002 | -$255.90K | - | - |
FAQ
- What is Catalyst Pharmaceuticals, Inc. annual EBITDA?
- What is the all-time high annual EBITDA for Catalyst Pharmaceuticals, Inc.?
- What is Catalyst Pharmaceuticals, Inc. annual EBITDA year-on-year change?
- What is Catalyst Pharmaceuticals, Inc. quarterly EBITDA?
- What is the all-time high quarterly EBITDA for Catalyst Pharmaceuticals, Inc.?
- What is Catalyst Pharmaceuticals, Inc. quarterly EBITDA year-on-year change?
- What is Catalyst Pharmaceuticals, Inc. TTM EBITDA?
- What is the all-time high TTM EBITDA for Catalyst Pharmaceuticals, Inc.?
- What is Catalyst Pharmaceuticals, Inc. TTM EBITDA year-on-year change?
What is Catalyst Pharmaceuticals, Inc. annual EBITDA?
The current annual EBITDA of CPRX is $233.18M
What is the all-time high annual EBITDA for Catalyst Pharmaceuticals, Inc.?
Catalyst Pharmaceuticals, Inc. all-time high annual EBITDA is $233.18M
What is Catalyst Pharmaceuticals, Inc. annual EBITDA year-on-year change?
Over the past year, CPRX annual EBITDA has changed by +$113.22M (+94.39%)
What is Catalyst Pharmaceuticals, Inc. quarterly EBITDA?
The current quarterly EBITDA of CPRX is $75.68M
What is the all-time high quarterly EBITDA for Catalyst Pharmaceuticals, Inc.?
Catalyst Pharmaceuticals, Inc. all-time high quarterly EBITDA is $75.76M
What is Catalyst Pharmaceuticals, Inc. quarterly EBITDA year-on-year change?
Over the past year, CPRX quarterly EBITDA has changed by +$15.25M (+25.24%)
What is Catalyst Pharmaceuticals, Inc. TTM EBITDA?
The current TTM EBITDA of CPRX is $296.64M
What is the all-time high TTM EBITDA for Catalyst Pharmaceuticals, Inc.?
Catalyst Pharmaceuticals, Inc. all-time high TTM EBITDA is $296.64M
What is Catalyst Pharmaceuticals, Inc. TTM EBITDA year-on-year change?
Over the past year, CPRX TTM EBITDA has changed by +$85.00M (+40.16%)